Cleo Diagnostics Ltd (COV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cleo Diagnostics Ltd (COV) has a cash flow conversion efficiency ratio of -0.189x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.67 Million ≈ $-1.18 Million USD) by net assets (AU$8.83 Million ≈ $6.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cleo Diagnostics Ltd (COV) balance sheet quality index to measure how much of total assets are equity-financed.
Cleo Diagnostics Ltd - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how Cleo Diagnostics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore COV cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Cleo Diagnostics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cleo Diagnostics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aviation Links Ltd
TA:AVIA
|
0.028x |
|
Abocom Systems Inc
TW:2444
|
-0.115x |
|
Power Minerals Ltd
AU:PNN
|
-0.070x |
|
SJM Co Ltd
KO:123700
|
0.046x |
|
US Energy Corp
NASDAQ:USEG
|
-0.006x |
|
Concraft Holding Co Ltd
TW:4943
|
0.011x |
|
Aztec Minerals Corp
V:AZT
|
-0.013x |
|
Australian Mines Ltd
AU:AUZ
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Cleo Diagnostics Ltd (2023–2025)
The table below shows the annual cash flow conversion efficiency of Cleo Diagnostics Ltd from 2023 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Cleo Diagnostics Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$5.83 Million ≈ $4.13 Million |
AU$-2.90 Million ≈ $-2.05 Million |
-0.497x | -130.03% |
| 2024-06-30 | AU$9.39 Million ≈ $6.65 Million |
AU$-2.03 Million ≈ $-1.44 Million |
-0.216x | -129.79% |
| 2023-06-30 | AU$-943.41K ≈ $-667.52K |
AU$-684.47K ≈ $-484.31K |
0.726x | -- |
About Cleo Diagnostics Ltd
Cleo Diagnostics Ltd, a biotechnology company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing int… Read more